Abstract
e14600 Background: After the Italian Drug Agency (AIFA) approval of cetuximab in mCRC KRASwt, the ObsrvevEr Study was initiated to evaluated quality of life (QoL), skin toxicity management and compliance of cetuximab based regimens in first-line chemotherapy (CT) Methods: ObservEr is a non interventional, observational, prospective study. The primary end point is the evaluation of QoL. Data on QoL (Dermatology Life Quality Index/DLQI, EORTC QLQ-C30) is assessed at baseline and weekly for the first 8 weeks of treatment Results: Between April 2011-November 2012, 233 pts were enrolled in 29 Italian centers, with 229 evaluable pts. Pt characteristics were: 154(67.2%) M, 75(32.8%) F; median age 65y (39-81); ECOG PS-0 78.2%, PS-1 21.8%%; adjuvant CT 81(35.4%); only liver metastasis 98(42.8%). Median interval between request and result of KRAS test in all Italian regions was 10d. The CT regimens in combinations with cetuximab were: IRI-based 149(65.1%), OXA-based 67(29.3%). Capecitabine regimens were administere...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
